Background Sorafenib, which is approved for treatment of HCC, has also shown promising antifibrotic activity, and therefore refinement of its dosing requirements and window of efficacy are important goals prior to antifibrotic clinical trials. Aim The purpose of this study was to determine the minimal effective dose and optimal timing of sorafenib therapy in cultured human stellate cells and in rats with experimental hepatic fibrosis. Methods Effects of sorafenib were assessed in a human stellate cell line (LX-2). In vivo, rats were treated for 8 weeks with TAA three times per week (150 mg/kg IP), and with either PBS or sorafenib administered daily at doses of 1.25, 5 or 7 mg/kg/day gavage either at the beginning of TAA administration for 8 weeks, during weeks 4-8, or from weeks 8-12.
Introduction
Liver fibrosis is a reversible wound healing response results from accumulation of extracellular matrix (ECM) in response to acute or chronic liver injury [1] . Hepatic stellate cells (HSC) are resident perisinusoidal cells in the subendothelial space between hepatocytes and sinusoidal endothelial cells that are the primary effector cells of liver fibrosis. During liver injury, HSCs are activated and produce most of the matrix components of fibrotic liver, including collagen. Platelet-derived growth factor (PDGF) is a potent mitogen of HSCs and is among one of the bestcharacterized pathways of HSC activation [2] . Induction of b-PDGF receptor during early HSC activation activates its downstream effectors, which include ERK/MAP kinase pathways [3, 4] . Anti-fibrotic drugs antagonizing b-PDGF Feng Hong and Hsini Chou contributed equally to this work.
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receptors and related tyrosine kinase receptors are appealing prospects for antifibrotic therapies.
Sorafenib is a widely used multi-tyrosine kinase inhibitor that is an FDA approved drug for treatment of hepatocellular and renal cell carcinomas [5] [6] [7] . Its mechanism of action is primarily to inhibit the RAF/MEK/ERK pathways, and in vivo it decreases tumor cell proliferation and angiogenesis, while increasing tumor cell apoptosis [8] . Previous studies demonstrate an anti-fibrotic activity of sorafenib in attenuating matrix accumulation and vascular remodeling in a bile duct ligation (BDL) model of liver fibrosis [9] . However, these studies have not established until what point during the natural progression of fibrosis sorafenib remains effective, and have not examined models of parenchymal cell injury and fibrosis, which is a far more common pattern of injury in human disease.
Development of antifibrotic therapies suitable for human use remains an elusive goal. In this study, we have examined the dosing requirement and window of efficacy of sorafenib treatment in an animal model, as a prelude to contemplating anti-fibrotic clinical trials in patients with fibrotic liver disease. Specifically, we have established the minimal effective dose and optimal timing of sorafenib therapy in cultured human HSCs and in the thioacetamide (TAA)-induced model of liver fibrosis in rats, a well-established model that most closely mimics human liver fibrosis.
Materials and Methods

Culture Studies
LX-2 cells and primary human stellate cells were maintained in Dulbecco's Modified Eagle Medium with high glucose containing 10 % fetal bovine serum and 1 % penicillin-streptomycin antibiotics (Gibco, Invitrogen). Cells were treated with sorafenib (Bayer Onyx) for 12, 24, 48 or 72 h at concentrations of 7.5 and 15 lM in medium with 0.2 % BSA or 10 % fetal bovine serum.
AlamarBlue
Ò Cell Viability Assay
Cell viability was assessed using AlamarBlue Ò (Invitrogen). A 96-well plate containing approximately 5,000 LX-2 cells per well were treated with 7.5 and 15 lM at 12 and 24 h. AlamarBlue Ò reagent is added directly to each well, the plates are incubated at 37°C to allow cells to convert resazurin to resorufin, and the fluorescence signal is measured.
Isolation of Primary Human HSCs
Primary HSCs were isolated from wedge sections of normal human livers in patients undergoing hepatic resection for primary benign tumors or single metastasis from colon cancer as previously described [10] . HSCs were activated by culturing on plastic for 7-14 days and subcultured to passage 3 for the following experiments. In addition to primary HSCs, we also utilized a well-validated immortalized human HSC line, LX-2, whose features closely resemble those of primary activated HSCs [11] .
Cell Proliferation Assay DNA synthesis was assayed using 3 H-thymidine incorporation as previously described [11] . LX-2 cells were seeded at a density of 20,000 cells per well in 24-well plates. After 24 h, the medium was changed to Dulbecco's Modified Eagle medium containing 0.2 % fetal bovine serum for 12 h, and the cells were then treated with sorafenib at 7.5 lM and 15 lM for an additional 24 or 48 h, and 1 lCi/mL 3 H-thymidine was added for 4 h before harvesting. Cells were then washed three times with ice-cold PBS and fixed in methanol for 30 min at 4°C. Cells were solubilized in 0.25 % sodium hydroxide/0.25 % sodium dodecyl sulfate. After neutralization with hydrochloric acid (1N), radioactivity was measured using a scintillation counter (Beckman Coulter).
DNA Isolation and Electrophoresis
To detect fragmented or apoptotic DNA (small DNA fragments) in LX-2 cells, DNA was isolated from LX-2 cells treated with 10 lg/mL of sorafenib and vehicle for 12 and 48 h using the Apoptotic DNA Ladder Extraction Kit (BioVision, Mountain View, USA) according to the manufacturer's guidelines. Samples were run in 2 % agarose gels, stained with ethidium bromide, and visualized by transillumination with UV light.
Reverse Transcription and Real-Time Quantitative PCR RNA from LX-2 cells, primary stellate cells or 100 mg of rat whole liver tissues were extracted and purified using an RNeasy Mini kit (Qiagen, Valencia, CA, USA), and 1 lg of total mRNA was reverse transcribed into complementary DNA (cDNA) using SprintTM RT Complete-RNA to cDNA EcoDry TM Premix (Double Primed) tubes (Clontech, Mountain View, CA) and analyzed by quantitative PCR using SYBR green qPCR Master Mix (Roche) on the LightCycler Ò 480 Real-Time PCR System (Roche). Data are represented as the relative expression of fibrogenic genes after normalizing to GAPDH.
Western Blot
Total protein was extracted from cells using RIPA lysis buffer (50 mM Tris-HCl pH = 8, 150 mM NaCl, 1 % IGEPAL, 0.5 % sodium deoxycholate and 0.1 % SDS) with protease and protein phosphatase inhibitor mixtures (Roche). Proteins from rat liver tissues were extracted by homogenizing. Protein concentration was determined with a Bio-Rad DC kit (Bio-Rad). Antibodies used were as follows: rabbit anti-collagen type I (1:2,000) (Rockland), mouse anti-aSMA (1:500) (Millipore), and rabbit anti-GAPDH (1:2,000) (Santa Cruz).
In Vivo Studies in TAA-Treated Rats Male Sprague-Dawley rats between 280 and 300 g or 8 and 10 weeks old (Jackson Laboratory) were maintained according to NIH guidelines and approved by the Mount Sinai IACUC Committee. Rats were kept in the Animal Care Facility of the Mount Sinai Medical Center with a 12-h light-dark cycle at constant temperature. Rats had free access to tap water during the study period.
In vivo studies employed ''prophylactic'' (group 2), ''therapeutic'' (group 3) and ''reversal'' (group 4) treatment schedules and a control group (group 1) (Supplemental Fig. 1 ). Each group contained four different subgroups, each of which contained seven rats. In group 1, rats were administered phosphate buffer saline (PBS) intraperitoneally (IP) weekly with no TAA injection. In groups 2, 3 and 4, rats were administered 150 mg/kg of TAA (Sigma Chemical Co., St. Louis, MO, USA) by IP, three times weekly for 8 weeks to induce cirrhosis. Rats were administered sorafenib by gavage daily at doses of 1.25 mg/kg/ day (subgroup A), 5 mg/kg/day (subgroup B), 7 mg/kg/day (subgroup C) and vehicle control (12.5 % Cremaphor [Sigma], 12.5 % ethanol and 75 % water) (subgroup D), beginning either concurrently with TAA for 8 weeks (Group 2), during weeks 4-8 (Group 3), or from weeks 8 to 12 after TAA was discontinued (group 4).
At the time of sacrifice, portal pressure was measured using a 16G angiocatheter introduced into the portal vein to measure the height of a water column. Blood was collected in EDTA containing microfuge tubes, pelleted at 5,000 rpm for 10 min, and plasma samples were obtained for AST, ALT, creatinine and bilirubin, and the liver was removed, weighed and processed. Spleen was also removed and weighed before being discarded.
Liver Histology and Fibrosis Quantification
Livers were fixed in 3.7 % formalin, embedded in paraffin and sectioned. Liver sections were stained with 0.1 % Sirius red in saturated picric acid (both from Sigma Chemical Co.). Four picrosirius red-stained slides per animal were taken, with nine images taken randomly per slide for a total of 36 images per animal for collagen quantification using computerized BIOQUANT Life Science morphometry Ò system.
Statistical Analysis
Data are presented as mean ± SD from at least three independent determinations. Comparisons were performed by two-tailed Student's t test. Data were considered to be statistically significant with p \ 0.05.
Results
Effects of Sorafenib on the Human Stellate Cell Line, LX-2
Previous studies demonstrated that sorafenib inhibits cell proliferation and viability in a dose-dependent matter and induces apoptosis in HSCs [12] . Consistent with these results, concentrations of 7.5 and 15 lM, sorafenib significantly inhibited LX-2 proliferation by more than 75 % at both doses and time points examined (Fig. 1) . Toxicity was observed as low as 3.5 lM (data not shown). To confirm apoptosis and reduced viability in the presence of sorafenib, DNA fragmentation was detected (Fig. 2 ) at 48 h, and a significant reduction of mitochondrial activity of up to 80 % at 48 h was also observed (Fig. 3) . We next assessed the impact of sorafenib on a panel of fibrogenic mRNAs assessed by real time PCR (Fig. 4) . In cells treated with sorafenib at concentration of 7.5 lM for 12, 24 and 48 h, there was a consistent down-regulation of mRNAs encoding collagen a1(I) [Colla 1 (1) ], tissue inhibitor of metalloproteinase type 1 (TIMP1), and matrix Assessment of Colla 1 (I) and a-SMA protein expression in LX-2 cells with Western blotting confirmed that sorafenib inhibited Colla 1 (I) protein expression at 15 lM but not 7.5 lM, while a-SMA expression was slightly inhibited at 24 h (Fig. 5a) . This was also shown in primary human stellate cells (HSC), however the a-SMA level was not affected (Fig. 5b) .
Anti-Fibrotic Effects of Sorafenib on Hepatic Fibrosis Induced by TAA In Vivo
In order to study the direct effect of sorafenib on liver fibrosis, we performed in vivo studies using the rat model of liver injury induced by TAA [13, 14] . Sorafenib has not been previously assessed in a parenchymal injury model due to TAA, which more resembles human disease because it less necrotic and inflammatory than CCl 4 induced liver injury [13] . Also, spontaneous reversibility is minimal after 5-6 weeks of TAA administration (data not shown). Four different dosing schedules were used in which all animals were administered TAA for 8 weeks with either vehicle or sorafenib for 4 or 8 weeks (Supplemental Fig. 1 ): group 1, a control group where rats were injected with PBS weekly was used for statistical comparison; group 2, a ''prophylactic'' regimen in which both TAA and sorafenib were administered concurrently; group 3, a ''therapeutic'' regimen in which sorafenib was initiated only 4 weeks after the beginning of an 8-week TAA dosing and continued for another 4 weeks thereafter; and group 4, a ''reversibility'' Combined data from real time PCR, Western blot, Sirius red staining and Bioquant collagen quantitation (Figs. 6, 7,  8 ) demonstrated that sorafenib was most effective in the ''therapeutic'' treatment group (group 3), while the ''prophylactic'' regimen (group 2) showed non-dose dependent efficacy, whereas the drug was ineffective in the ''reversibility'' (group 4) (data not shown).
In the ''therapeutic'' group (group 3), there was consistent down-regulation of fibrogenic genes including Colla 1 (I) and Colla 2 (I) (Fig. 6) , consistent with collagen quantitation by morphometry, which documented a 70 % decrease in collagen area compared to vehicle-injected livers (Fig. 7) . Sorafenib also down-regulated mRNAs for MMP2, a-SMA, b-PDGFR and TGFbR1 (Fig. 6 ). There were no significant changes in mRNA expression or collagen reduction in group 4 (data not shown).
There were no significant differences in the liver weight to body weight ratio in all subgroups except for animals in group 2 treated with 5 mg/kg/day of sorafenib, where the ratio was reduced compared with the corresponding control vehicle subgroup (Table 1 ). There were no significant differences in portal pressure between subgroups (see Supplemental Figs. 2, 3 and 4) .
Sorafenib Inhibits Expression of a-SMA Protein in TAA-Treated Rat Liver
As shown in Fig. 8a,b , western blot confirmed that a-SMA was markedly decreased in animals treated with sorafenib either at the beginning of TAA treatment (group 2) or during weeks 4-8 (group 3). In contrast, there was no significant effect of sorafenib on a-SMA protein expression when treatment started 8 weeks post TAA administration, where cirrhosis was already established (data not shown).
Discussion
Previous reports have demonstrated that sorafenib inhibits the proliferative activity of tumor cells and HSCs by targeting the tyrosine kinases associated with bPDGF receptor and Raf/ERK signaling pathways [4, 5, 8, 15] . In the present study, we demonstrate that sorafenib inhibited proliferation of a human HSC line by more than 75 % at 7.5 and 15 lM within 24 h, as assessed by 3 H thymidine incorporation. In addition to inhibiting HSCs proliferation, sorafenib induced LX-2 cellular apoptosis (Fig. 2) , an important finding since HSC apoptosis promotes the resolution of liver fibrosis [16] .
Activated HSCs produce the bulk of the ECM proteins of the fibrotic liver including fibrillar and non-fibrillar collagens [17, 18] . TGFb is a pro-fibrogenic cytokine derived from both paracrine and autocrine sources, and is a strong stimulus for collagen I production by activated HSCs [19, 20] . In our experiments, sorafenib suppressed TGFb1 and Coll1 in vivo and in culture, which correlated with changes in protein expression by western blot (Figs. 5, 8). Sorafenib reduced collagen deposition by more than 60 % when begun 4 weeks after TAA administration started (group 3), with efficacy even at 1.25 mg/kg/day (Fig. 7b) , as well as at higher doses, based on real-time PCR data and collagen quantitation (Fig. 7c, d ). This reduction of collagen deposition was paralleled by a significant suppression of collagen a 1 (I) and a 2 (I) mRNAs in whole liver (Fig. 6 ). In addition, decreased pro-fibrogenic Fig. 7 Liver fibrosis was greatly reduced in rat liver tissue in the ''therapeutic'' treatment group. a Histology of rat liver with H&E and Sirius red in representative liver sections from animals in group 3 at 9100 and 9200 magnifications. Relative fibrosis area (expressed as a percentage of total liver area) was assessed by analyzing 36 Sirius red-stained liver sections per animal. Each field was acquired at 9100 magnification and analyzed using a computerized Bioquant morphometry system. There was a statistically significant difference in fibrosis in the livers of animals treated with 1.25 mg/kg/day (b), 5 mg/kg/day (c) and 7 mg/kg/day (d) of sorafenib. *p \ 0.001 mRNAs reflects the inhibition of HSC activation, as documented by reduced levels of aSMA as well as TGFb1 mRNA expression in liver. Interestingly, the effect on aSMA expression was greater in vivo than in isolated stellate cells, which could suggest that some of the drug's impact on stellate cell activation is mediated through effects on neighboring cells, especially sinusoidal endothelial cells. In contrast to findings in group 3, there was no significant effect of sorafenib on fibrogenic gene expression or collagen deposition when treatment began 4 weeks after cirrhosis was established after 8 weeks of TAA treatment in group 4 (data not shown).
Fibrosis reflects a balance between ECM production and degradation mediated by MMPs and TIMPs, which play a key role in collagen degradation [21] . Consistent with earlier studies [12] , our results demonstrate that sorafenib significantly decreased TIMP1 mRNA expression in culture-activated HSCs, suggesting that the drug mediates a reduction in collagen deposition both by reducing type I collagen synthesis directly and indirectly by possibly increasing net matrix protease activity through decreased expression of TIMP-1, a key metalloproteinase inhibitor.
Our findings greatly refine the optimal parameters of clinical trials to assess sorafenib as an antifibrotic in human chronic liver disease. A primary effect on HSC activation in culture and in vivo is consistent with the drug's efficacy when administered during ongoing liver injury but not in established cirrhosis. Moreover, the lack of effects on serum AST and ALT indicates that sorafenib is primarily antifibrotic through its effects on fibrogenesis rather than by attenuating liver injury. Importantly, the drug's efficacy at relatively low doses means that antifibrotic dosing in humans can be lower than what is currently used for HCC treatment, which should improve tolerability and compliance. Moreover, the goal of antifibrotic therapy is to attenuate the rate of fibrosis progression but not necessarily to eliminate it altogether. With this goal in mind, the evaluation of sorafenib as an antifibrotic in humans merits further evaluation. 
